| Comparative tolerance and complications in a multicentre trial of intracoronary streptokinase and intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction. | |
| | |
MedLine Citation:
|
PMID: 3315606 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The safety and tolerance data of the preliminary results of a randomised, parallel group, multicentre trial of intracoronary streptokinase and intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in patients with myocardial infarction are presented. The frequency of side effects was similar in the 2 groups. The most frequently encountered side effect was bleeding, overwhelmingly from the groin puncture site from angiography. There was no significant difference between amount or incidence of bleeding complications between the two groups, as measured by number of bleeding episodes, transfusion requirements, or mean drop in haematocrit or haemoglobin. |
| | |
Authors:
|
R L Rothbard |
Related Documents
:
|
21309746 - C-terminal provasopressin (copeptin) as a prognostic marker after acute non-st elevatio... 8237806 - Effects of long-term oral magnesium chloride replacement in congestive heart failure se... 14739626 - Efficacy and safety of a new streptokinase regimen with enoxaparin in acute myocardial ... 10079776 - Potential cost effectiveness of tissue plasminogen activator among patients previously ... 11950436 - Prediction of mortality in heart transplant recipients by stress technetium-99m tetrofo... 15733666 - Normal patterning of the coronary capillary plexus is dependent on the correct transmur... |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial |
Journal Detail:
|
Title: Drugs Volume: 33 Suppl 3 ISSN: 0012-6667 ISO Abbreviation: Drugs Publication Date: 1987 |
Date Detail:
|
Created Date: 1988-01-07 Completed Date: 1988-01-07 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 7600076 Medline TA: Drugs Country: NEW ZEALAND |
Other Details:
|
Languages: eng Pagination: 276-8 Citation Subset: IM |
Affiliation:
|
University of Rochester, School of Medicine and Dentistry. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anistreplase Clinical Trials as Topic Fibrinolytic Agents / adverse effects*, therapeutic use Hematocrit Hemoglobins / drug effects Hemorrhage / chemically induced Humans Myocardial Infarction / drug therapy* Plasminogen / adverse effects*, therapeutic use Random Allocation Streptokinase / adverse effects*, therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Fibrinolytic Agents; 0/Hemoglobins; 81669-57-0/Anistreplase; 9001-91-6/Plasminogen; EC 3.4.-/Streptokinase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Biological study of intravenous anisoylated plasminogen streptokinase activator complex in acute myo...
Next Document: Safety and side effects of anisoylated plasminogen streptokinase activator complex and streptokinase...